Humacyte’s (HUMA) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a report published on Monday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

Other equities research analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st. UBS Group reiterated a “buy” rating on shares of Humacyte in a report on Monday, December 1st. BTIG Research restated a “buy” rating and set a $6.00 target price on shares of Humacyte in a research note on Friday, November 21st. Benchmark decreased their price target on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Humacyte in a research report on Monday, December 1st. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Humacyte has an average rating of “Moderate Buy” and a consensus target price of $8.14.

Humacyte Price Performance

Shares of HUMA stock opened at $1.22 on Monday. The stock’s 50-day moving average is $1.10 and its 200 day moving average is $1.47. Humacyte has a 1-year low of $0.88 and a 1-year high of $4.28. The company has a debt-to-equity ratio of 2.97, a current ratio of 1.62 and a quick ratio of 0.90. The company has a market cap of $228.47 million, a P/E ratio of -5.30 and a beta of 1.93.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The firm had revenue of $0.75 million during the quarter, compared to the consensus estimate of $0.92 million. Research analysts predict that Humacyte will post -1.27 earnings per share for the current fiscal year.

Institutional Trading of Humacyte

Several institutional investors and hedge funds have recently bought and sold shares of HUMA. Geode Capital Management LLC boosted its holdings in shares of Humacyte by 20.2% in the 4th quarter. Geode Capital Management LLC now owns 3,720,436 shares of the company’s stock valued at $3,574,000 after acquiring an additional 624,220 shares during the last quarter. Fisher Asset Management LLC purchased a new stake in Humacyte in the fourth quarter valued at $47,000. R Squared Ltd acquired a new stake in Humacyte during the 4th quarter worth about $25,000. UBS Group AG grew its position in Humacyte by 48.8% during the 4th quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock worth $2,862,000 after purchasing an additional 976,275 shares during the period. Finally, United Asset Strategies Inc. raised its stake in shares of Humacyte by 13.5% during the 4th quarter. United Asset Strategies Inc. now owns 209,608 shares of the company’s stock valued at $201,000 after buying an additional 25,000 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.